Table 2. Best response to crizotinib therapy.
Efficacy | ROS1, n=26 | ALK, n=42 | P value |
---|---|---|---|
Response | |||
CR | 2 (8%) | 5 (12%) | |
PR | 16 (62%) | 24 (57%) | |
SD | 4 (15%) | 5 (12%) | |
PD | 2 (8%) | 3 (7%) | |
NE | 2 (8%) | 5 (12%) | |
Clinical benefit | |||
ORR | 69% | 69% | 0.987 |
DCR | 85% | 81% | 0.484 |
ALK, anaplastic lymphoma kinase; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not estimable; ORR, objective response rate; DCR, disease control rate.